Blair William & Co. IL Has $30.46 Million Stock Holdings in Edwards Lifesciences Corporation (NYSE:EW)

Key Points

• Blair William & Co. IL reduced its position in Edwards Lifesciences Corporation by 20.2% during the first quarter, now holding 420,226 shares valued at approximately $30.46 million.
• Edwards Lifesciences reported earnings of $0.67 per share, exceeding analysts' expectations, with quarterly revenue reaching $1.53 billion, a year-over-year increase of 11.9%.
• Despite recent stock fluctuations, several analysts have raised their price targets for Edwards Lifesciences, with a consensus rating of "Moderate Buy" and an average target price of $85.71.

Blair William & Co. IL cut its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 20.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 420,226 shares of the medical research company's stock after selling 106,066 shares during the quarter. Blair William & Co. IL owned 0.07% of Edwards Lifesciences worth $30,458,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC acquired a new stake in Edwards Lifesciences during the fourth quarter valued at approximately $266,000. Bank Pictet & Cie Europe AG raised its position in Edwards Lifesciences by 16.7% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 10,231 shares of the medical research company's stock worth $757,000 after purchasing an additional 1,463 shares during the last quarter. Arete Wealth Advisors LLC raised its position in Edwards Lifesciences by 20.4% in the 4th quarter. Arete Wealth Advisors LLC now owns 4,139 shares of the medical research company's stock worth $307,000 after purchasing an additional 700 shares during the last quarter. ExodusPoint Capital Management LP bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $2,253,000. Finally, Wells Fargo & Company MN raised its position in shares of Edwards Lifesciences by 10.6% during the 4th quarter. Wells Fargo & Company MN now owns 844,023 shares of the medical research company's stock valued at $62,483,000 after acquiring an additional 81,144 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Down 0.0%

Edwards Lifesciences stock opened at $79.30 on Monday. Edwards Lifesciences Corporation has a fifty-two week low of $59.41 and a fifty-two week high of $83.00. The stock has a market cap of $46.52 billion, a PE ratio of 11.41, a price-to-earnings-growth ratio of 3.84 and a beta of 1.08. The firm's 50-day simple moving average is $76.91 and its 200 day simple moving average is $73.85. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 4.45.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.25%. The company's quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.70 earnings per share. Research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 4,114 shares of the company's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 2,570 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $77.40, for a total transaction of $198,918.00. Following the completion of the transaction, the vice president directly owned 50,356 shares of the company's stock, valued at approximately $3,897,554.40. This represents a 4.86% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,982 shares of company stock valued at $2,193,425. Corporate insiders own 0.34% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Piper Sandler boosted their price target on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the company an "overweight" rating in a report on Friday, July 25th. Morgan Stanley upped their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company an "equal weight" rating in a report on Tuesday, July 15th. Argus raised shares of Edwards Lifesciences to a "strong-buy" rating in a report on Thursday, July 10th. Stifel Nicolaus increased their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "buy" rating in a research report on Friday, July 25th. Finally, Citigroup restated a "buy" rating and issued a $95.00 target price (up previously from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, thirteen have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $85.71.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.